Mergers & Acquisitions
🇺🇸 FDA Page 5FDA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page
Track global pharma M&A deals, divestitures, and partnerships. Gain critical intelligence for strategic investment and business development in life sciences.
Showing 49–60 of 64 articles
Gilead's $140M Deal with Yuhan: What It Means for Pharma
Gilead Sciences has signed a significant $140M deal with Yuhan, a Korean API manufacturer. This article explores the implications for the pharmaceutical landscape.
Bristol Myers Expands AI Capabilities with Anthropic Partnership
Bristol Myers has deepened its investment in artificial intelligence by partnering with Anthropic. This strategic move aims to enhance its drug development capabilities and competitive edge.
Gilead's $140M Deal with Yuhan: Implications for Pharma
Gilead Sciences has signed a significant $140M deal with Korean API manufacturer Yuhan. This article explores the implications for the pharmaceutical landscape.
Roche's Licensing Deal for Generic Xofluza: Implications and Insights
Roche has signed a licensing deal for generic Xofluza with the Medicines Patent Pool, impacting 129 countries. This article explores the implications for pharma teams and investors.
Supreme Court Decision on IRA Challenges: Implications for Pharma
The Supreme Court's decision not to hear IRA challenges from Novo and AstraZeneca signals significant implications for the pharmaceutical industry, particularly in drug pricing strategies.
Supreme Court's IRA Decision: Implications for Pharma Deals
The Supreme Court's refusal to hear IRA challenges from Novo and AstraZeneca has significant implications for the pharmaceutical industry. This article explores the potential impacts on business development and investment strategies.
Supreme Court's Impact on Pharma Pricing Strategies
The Supreme Court's recent decision not to hear IRA challenges from Novo and AstraZeneca could reshape drug pricing strategies. This article explores the implications for pharma executives and investors.
Regeneron Secures $125M Parabilis Deal for Drug Targets
Regeneron has entered a significant $125M deal with Parabilis to target elusive drug targets. This partnership could reshape competitive dynamics in the pharmaceutical industry.
Pfizer's Latest Developments: Insights for Investors and Executives
This article analyzes Pfizer's recent developments, focusing on their implications for business development teams and investors. Discover key insights and strategic impacts.
U.K. Advocacy Groups Challenge U.S. Pharma Trade Deal
U.K. advocacy groups are threatening court action over a crucial provision in the U.S. pharma trade deal. This could have significant implications for the pharmaceutical industry.
Biopharma M&A Trends: Resilience Amidst Large Deal Decline
Despite a noticeable decline in large biopharma mergers and acquisitions, the overall M&A landscape remains robust. This article explores the implications for business development teams and investors.
M&A Trends: Mid-Size Pharma Companies on the Rise
Mid-size pharmaceutical companies are stepping up their M&A activities, challenging the dominance of big pharma. This article explores the implications for business development teams and investors.